Immunogenicity after switching from reference infliximab to biosimilar in children with Crohn's disease

被引：0
|
作者：
Sieczkowska, J. [1 ]
Jarzebicka, D. [1 ]
Oracz, G. [1 ]
Meglicka, M. [1 ]
Dadalski, M. [1 ]
Kierkus, J. [1 ]
机构：
[1] Childrens Mem Hlth Inst, Dept Gastroenterol Hepatol Feeding Disorders & Pa, Warsaw, Poland
来源：
JOURNAL OF CROHNS & COLITIS | 2016年 / 10卷
关键词：
D O I：
暂无
中图分类号：
R57 [消化系及腹部疾病];
学科分类号：
摘要：
P617
引用
收藏
页码：S413 / S414
页数：2
相关论文
共 50 条
  • [31] Disease activity and quality of life in Crohn's-associated spondyloarthropathy after switching from infliximab to adalimumab
    Antivalle, M.
    Bertani, L.
    Atzeni, F.
    Battellino, M.
    Batticciotto, A.
    Montalbono, F.
    Mutti, A.
    Sarzi-Pullini, P.
    CLINICAL AND EXPERIMENTAL RHEUMATOLOGY, 2008, 26 (04) : 746 - 746
  • [32] Biosimilar Infliximab: Is intracellular signaling the same after switching?
    Aarebrot, A. K.
    Solberg, S. M.
    Davies, R.
    Eidsheim, M.
    Jakobsen, K.
    Bader, L.
    Gavasso, S.
    Bryceson, Y.
    Holmes, T. D.
    Sandvik, L. F.
    Jonsson, R.
    Appel, S.
    EXPERIMENTAL DERMATOLOGY, 2016, 25 : 35 - 35
  • [33] Preliminary Assessment of Efficacy and Safety of Switching Between Originator and Biosimilar Infliximab in Paediatric Crohn Disease Patients
    Kierkus, Jaroslaw
    GASTROENTEROLOGY, 2015, 148 (04) : S782 - S783
  • [34] A case report of drug-induced liver injury due to the infliximab biosimilar CT-P13 on switching from original infliximab in a patient with Crohn's disease
    Kashima, Shin
    Sawada, Koji
    Moriichi, Kentaro
    Fujiya, Mikihiro
    THERAPEUTIC ADVANCES IN DRUG SAFETY, 2022, 13
  • [35] In patients with Crohn's disease, timing of switching from infliximab to adalimumab affects prognosis
    Takeuchi, K.
    Yamada, A.
    Suzuki, Y.
    JOURNAL OF CROHNS & COLITIS, 2014, 8 : S249 - S249
  • [36] Autoimmune Hepatitis Induced by Infliximab in a Patient with Crohn's Disease with no Relapse After Switching to Adalimumab
    Cravo, Marilia
    Silva, Rosa
    Serrano, Miguel
    BIODRUGS, 2010, 24 : 25 - 27
  • [37] Autoimmune Hepatitis Induced by Infliximab in a Patient with Crohn’s Disease with no Relapse After Switching to Adalimumab
    Marilia Cravo
    Rosa Silva
    Miguel Serrano
    BioDrugs, 2010, 24 : 25 - 27
  • [38] Subjective Complaints as the Main Reason for Biosimilar Discontinuation After Open-Label Transition From Reference Infliximab to Biosimilar Infliximab
    Tweehuysen, Lieke
    van den Bemt, Bart J. F.
    van Ingen, Iris L.
    de Jong, Alphons J. L.
    van der Laan, Willemijn H.
    van den Hoogen, Frank H. J.
    den Broeder, Alfons A.
    ARTHRITIS & RHEUMATOLOGY, 2018, 70 (01) : 60 - 68
  • [39] Quantitative benefit-risk modelling of infliximab biosimilar inflectra versus reference product remicade in the treatment of Crohn's disease
    Catt, Heather
    Hughes, Dyfrig
    Bodger, Keith
    Kirkham, Jamie
    TRIALS, 2017, 18
  • [40] Adalimumab and infliximab biosimilar ameliorated cachexic syndrome of Crohn Disease
    Hahm, K. B.
    Han, Y. M.
    Park, J. M.
    Kang, E. A.
    JOURNAL OF CROHNS & COLITIS, 2018, 12 : S138 - S138
12345